Sentences with phrase «lung cancer research at»

asks Paul Bunn Jr., MD, FASCO, distinguished professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine.

Not exact matches

She spoke at Genentech, a cancer research firm, exchanged e-mails with half a dozen other cancer patients nationwide and was interviewed on NPR as a voice of nonsmoker lung - cancer sufferers.

Smoking in cars can expose children's lungs to levels of carcinogens and toxins at rates 10 times higher than when smoking was permitted in bars, added Dr. Mark Travers, a research scientist in the Division of Cancer Prevention and Population Sciences at Roswell.

«Our study suggests that epigenetic changes to cells treated with cigarette smoke sensitize airway cells to genetic mutations known to cause lung cancers,» says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and professor of oncology at the Johns Hopkins Kimmel Cancer Center.

While pursuing her project on how environmental contaminants and oxidative stress cause lung cancer, Gelhaus complemented her postdoctoral training by spending some time with other PIs at Penn. «She has worked hard to develop skills that are independent of those available in my own laboratory while working on a project that is central to my research program,» Blair writes in an e-mail to Science Careers.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.

A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Researchers at the Menzies Centre for Population Health Research in Hobart have found that in Tasmania between 1983 and 1992, there were almost twice as many lung cancer cases among women aged between 25 and 44 years as in men of the same age.

«If you look at a set of lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hoscancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hoscancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's HosCancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.

Research at the school seeks new cures and treatments in five key areas: cancer, liver disease, heart / lung disease, aging and brain disease, and infectious disease.

The research, presented at the European Respiratory Society (ERS) International Congress in Munich, suggests that testing the temperature of breath could be a simple and noninvasive method to either confirm or reject the presence of lung cancer.

Lung cancer in particular has become the «poster child» for how research and treatment have changed, says Charles Swanton, a research oncologist at the Francis Crick Institute in London, England.

Seemingly healthy cells may in fact hide clues that lung cancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer Instcancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer InstCancer Center The research is published online in the Journal of the National Cancer InstCancer Institute.

Previous research, including pioneering work at MD Anderson by this study's senior author Ignacio Wistuba, M.D., and others, has shown normal - appearing tissue close to lung premalignant and cancer lesions may have tumor - associated molecular abnormalities.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

A lung cancer diagnosis appears to put patients at the greatest risk of suicide when compared to the most common types of non-skin cancers, according to new research presented at the ATS 2017 International Conference.

Scientists from the Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer cancer cells.

Cancer Research UK scientists have found a drug combination that can trigger the self - destruct process in lung cancer cells — paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in LiveCancer Research UK scientists have found a drug combination that can trigger the self - destruct process in lung cancer cells — paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in LiResearch UK scientists have found a drug combination that can trigger the self - destruct process in lung cancer cells — paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Livecancer cells — paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liresearch that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in LiveCancer Research Institute (NCRI) Cancer Conference in LiResearch Institute (NCRI) Cancer Conference in LiveCancer Conference in Liverpool.

The Cancer Research UK team, based at the UCL Cancer Institute, has successfully fixed this fault in lung cancer cells — reprogramming the cells to self - desCancer Research UK team, based at the UCL Cancer Institute, has successfully fixed this fault in lung cancer cells — reprogramming the cells to self - desCancer Institute, has successfully fixed this fault in lung cancer cells — reprogramming the cells to self - descancer cells — reprogramming the cells to self - destruct.

«Advances in lung cancer therapy require a greater understanding of the molecular origins of this deadly disease,» said last corresponding author Levantini, who is also a researcher at the Institute of Biomedical Technologies at the Italian National Research Council (ITB - CNR).

Recent research has shown that lung CT screening of smokers with smoking histories of at least 30 - pack years can lead to early detection of lung cancer and reduce deaths by 20 percent.

Researchers from the Perelman School of Medicine at the University of Pennsylvania, along with the Institute for Health Research at Kaiser Permanente Colorado, Kaiser Permanente Hawaii, the Henry Ford Health System in Detroit, and Marshfield Clinic Health System in Wisconsin, have received a five - year, $ 15.5 million National Cancer Institute (NCI) grant to improve lung cancer screCancer Institute (NCI) grant to improve lung cancer screcancer screening.

The National Heart, Lung and Blood Institute of the U.S. Department of Health and Human Services, the National Cancer Institute and Wyeth - Ayerst Research Laboratories funded the study, which involved researchers at nine institutions and 15 WHI clinical - study sites nationwide.

Commenting on the significance of the research, Dr Pilar Garrido, head of the Thoracic Tumour Section of the Medical Oncology Department at Ramón y Cajal University Hospital, Madrid, Spain, said: «Lung cancer is the most common cancer globally, but debate about the optimal screening strategy is ongoing and current selection criteria are based only on age and pack - years.

DENVER — A pre-competitive consortia of pharmaceutical, diagnostic companies and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the «BLUEPRINT PD - L1 IHC ASSAY COMPARISON PROJECT» at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19.

MD Anderson's Institute for Applied Cancer Science (IACS) in combination with Deerfield will provide drug discovery and development expertise, together with translational research focused at advancing autophagy therapeutics into trials in melanoma, lung and pancreatic cancers.

Personalised medicine is becoming relevant in the treatment of lung cancer [42, 43] and may have relevance for other lung diseases, like pulmonary fibrosis, asthma and pulmonary hypertension, but disease - related basic research aimed at searching for biomarkers is needed to achieve personalised and patient - specific treatments for lung diseases.

The international early Phase II trial led by a team based at the Oxford Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this group.

In addition to his role at Chicago Center for Health Equity Research, Robert Winn is the primary investigator in a lab at the University of Illinois at Chicago that explores signaling pathways in lung cancer.

This work was supported by University of California at Los Angeles Specialized Program of Research Excellence In Lung Cancer NIH grant P50 CA90388, UC Tobacco - Related Disease Research Program 13RT - 0031, NIH RO1 CA111851 and Merit Review Research Funds from the Department of Veterans Affairs.

Long - term use of aspirin is associated with lower risk of dying from various types of cancers, including colorectal, lung, breast and prostate cancer, according to a study presented at the 2017 American Association for Cancer Research annual mecancer, according to a study presented at the 2017 American Association for Cancer Research annual meCancer Research annual meeting.

Lung Cancer is approached at Penn in a multidisciplinary fashion from both the clinical and research perspective using the infrastructure of the Abramson Cancer Center's interdisciplinary Thoracic Oncology Program (ITOP).

Reykjavik, ICELAND, January 19, 2009 — Scientists at deCODE genetics (Nasdaq: DCGN) and colleagues from the US and ten European countries today announced a long - awaited first in cancer research: the discovery of common single - letter variations in the human genome (SNPs) linked to susceptibility not of one, but several different types of cancer, including those of lung, bladder, prostate, skin and cervix.

• Cancer prevention: A 2009 review of 51 green tea studies found that sipping three to five cups a day may lower the risks of ovarian, colorectal, lung, and prostate cancers, but not breast or other cancers, says lead author Katja Boehm, research fellow at the Center of Integrative Medicine at the University of Witten / Herdecke in Germany.

The findings were reported at the American Association for Cancer Research - International Association for the Study of Lung Cancer Joint Conference on Molecular Origins of Lung Cancer.

Washington, DC About Blog Lung Cancer Alliance is dedicated to saving lives and advancing research by empowering those living with or at risk for lung canLung Cancer Alliance is dedicated to saving lives and advancing research by empowering those living with or at risk for lung cCancer Alliance is dedicated to saving lives and advancing research by empowering those living with or at risk for lung canlung cancercancer.